Does the media refer more to AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 19 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.18 beat Jazz Pharmaceuticals' score of 0.58 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer JAZZ or ZTS?

In the previous week, Zoetis had 22 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 45 mentions for Zoetis and 23 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 0.77 beat Jazz Pharmaceuticals' score of 0.58 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Zoetis 22 Very Positive mention(s) 1 Positive mention(s) 21 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer JAZZ or RPRX?

In the previous week, Jazz Pharmaceuticals had 14 more articles in the media than Royalty Pharma. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.58 beat Jazz Pharmaceuticals' score of 0.58 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Royalty Pharma 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to JAZZ or CORT?

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Corcept Therapeutics. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 19 mentions for Corcept Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.58 beat Corcept Therapeutics' score of 0.52 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive Corcept Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SUPN or JAZZ?

In the previous week, Jazz Pharmaceuticals had 20 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.58 beat Supernus Pharmaceuticals' score of 0.28 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Jazz Pharmaceuticals (JAZZ) Competitors

$224.66 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$224.62 -0.04 (-0.02%)

As of 06/18/2026 07:37 PM Eastern

Compare

JAZZ vs. AXSM, ZTS, RPRX, CORT, and SUPN

Should you buy Jazz Pharmaceuticals stock or one of its competitors? MarketBeat compares Jazz Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jazz Pharmaceuticals include Axsome Therapeutics (AXSM), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "medical" sector.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	20.19	-$183.17M	-$3.73	N/A
Jazz Pharmaceuticals	$4.27B	3.31	-$356.15M	-$0.02	N/A

Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 19 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 1.18 beat Jazz Pharmaceuticals' score of 0.58 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Axsome Therapeutics currently has a consensus price target of $258.95, suggesting a potential upside of 3.37%. Jazz Pharmaceuticals has a consensus price target of $246.06, suggesting a potential upside of 9.52%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Zoetis?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Zoetis	27.80%	66.85%	18.79%

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Zoetis had 22 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 45 mentions for Zoetis and 23 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 0.77 beat Jazz Pharmaceuticals' score of 0.58 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Zoetis	22 Very Positive mention(s)	1 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Jazz Pharmaceuticals currently has a consensus target price of $246.06, indicating a potential upside of 9.52%. Zoetis has a consensus target price of $133.92, indicating a potential upside of 70.18%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.31	-$356.15M	-$0.02	N/A
Zoetis	$9.47B	3.48	$2.67B	$6.03	13.05

Summary

Zoetis beats Jazz Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Royalty Pharma (NASDAQ:RPRX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Royalty Pharma has a net margin of 33.88% compared to Jazz Pharmaceuticals' net margin of 0.66%. Royalty Pharma's return on equity of 29.25% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Royalty Pharma	33.88%	29.25%	14.71%

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Jazz Pharmaceuticals had 14 more articles in the media than Royalty Pharma. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.58 beat Jazz Pharmaceuticals' score of 0.58 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Royalty Pharma	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Jazz Pharmaceuticals presently has a consensus target price of $246.06, suggesting a potential upside of 9.52%. Royalty Pharma has a consensus target price of $53.71, suggesting a potential upside of 1.42%. Given Jazz Pharmaceuticals' higher possible upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.31	-$356.15M	-$0.02	N/A
Royalty Pharma	$2.38B	12.82	$770.95M	$1.47	36.03

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Jazz Pharmaceuticals presently has a consensus target price of $246.06, indicating a potential upside of 9.52%. Corcept Therapeutics has a consensus target price of $88.83, indicating a potential upside of 11.17%. Given Corcept Therapeutics' higher probable upside, analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corcept Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.31	-$356.15M	-$0.02	N/A
Corcept Therapeutics	$761.41M	11.27	$99.65M	$0.35	228.31

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	0.66%	14.56%	5.25%
Corcept Therapeutics	6.14%	7.40%	5.76%

In the previous week, Jazz Pharmaceuticals had 4 more articles in the media than Corcept Therapeutics. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 19 mentions for Corcept Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.58 beat Corcept Therapeutics' score of 0.52 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
Corcept Therapeutics	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Supernus Pharmaceuticals has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.58	-$38.55M	-$0.51	N/A
Jazz Pharmaceuticals	$4.27B	3.31	-$356.15M	-$0.02	N/A

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

In the previous week, Jazz Pharmaceuticals had 20 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 23 mentions for Jazz Pharmaceuticals and 3 mentions for Supernus Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.58 beat Supernus Pharmaceuticals' score of 0.28 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a net margin of 0.66% compared to Supernus Pharmaceuticals' net margin of -3.74%. Jazz Pharmaceuticals' return on equity of 14.56% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Supernus Pharmaceuticals presently has a consensus target price of $62.17, suggesting a potential upside of 40.08%. Jazz Pharmaceuticals has a consensus target price of $246.06, suggesting a potential upside of 9.52%. Given Supernus Pharmaceuticals' higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.11B	$3.41B	$6.43B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-11,227.39	19.73	24.75	24.42
Price / Sales	3.31	320.10	530.01	108.93
Price / Cash	13.81	127.84	45.07	55.09
Price / Book	3.16	8.16	10.80	6.58
Net Income	-$356.15M	$23.94M	$3.57B	$337.17M
7 Day Performance	-2.56%	2.57%	0.73%	0.83%
1 Month Performance	-6.00%	2.35%	1.35%	3.27%
1 Year Performance	108.97%	55.09%	29.31%	36.05%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	3.6698 of 5 stars	$224.66 flat	$246.06 +9.5%	+109.0%	$14.11B	$4.27B	N/A	2,890	Insider Trade High Trading Volume
AXSM Axsome Therapeutics	2.2693 of 5 stars	$235.14 +1.2%	$251.26 +6.9%	+148.8%	$11.96B	$638.50M	N/A	380	News Coverage Positive News Analyst Forecast Gap Up
ZTS Zoetis	4.9785 of 5 stars	$78.80 -0.8%	$133.92 +70.0%	-50.0%	$33.30B	$9.47B	13.07	14,500	Trending News
RPRX Royalty Pharma	4.6279 of 5 stars	$54.86 -1.8%	$53.71 -2.1%	+51.9%	$32.17B	$2.38B	37.32	80	Positive News Gap Up
CORT Corcept Therapeutics	3.725 of 5 stars	$73.33 +1.0%	$88.83 +21.1%	+12.0%	$7.80B	$761.41M	209.52	300	Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, ZTS, RPRX, CORT, and SUPN

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, ZTS, RPRX, CORT, and SUPN

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Do insiders & institutionals hold more shares of AXSM or JAZZ?

Which has higher earnings and valuation, AXSM or JAZZ?

Which has more risk & volatility, AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Does the media refer more to AXSM or JAZZ?

Do analysts prefer AXSM or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Is JAZZ or ZTS more profitable?

Do insiders and institutionals have more ownership in JAZZ or ZTS?

Does the media prefer JAZZ or ZTS?

Which has more risk & volatility, JAZZ or ZTS?

Do analysts recommend JAZZ or ZTS?

Which has better valuation & earnings, JAZZ or ZTS?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Is JAZZ or RPRX more profitable?

Do institutionals & insiders hold more shares of JAZZ or RPRX?

Does the media prefer JAZZ or RPRX?

Which has more volatility & risk, JAZZ or RPRX?

Do analysts recommend JAZZ or RPRX?

Which has better valuation and earnings, JAZZ or RPRX?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Do analysts recommend JAZZ or CORT?

Which has better earnings and valuation, JAZZ or CORT?

Which has more volatility and risk, JAZZ or CORT?

Is JAZZ or CORT more profitable?

Does the media refer more to JAZZ or CORT?

Do insiders and institutionals believe in JAZZ or CORT?

Summary

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Which has better valuation & earnings, SUPN or JAZZ?

Do institutionals & insiders believe in SUPN or JAZZ?

Which has more volatility and risk, SUPN or JAZZ?

Does the media favor SUPN or JAZZ?

Is SUPN or JAZZ more profitable?

Do analysts rate SUPN or JAZZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools